Deborah A. Lannigan

Deborah A. Lannigan


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2023 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
EWEric B. Wright
Eric B. Wright
DLDeborah A. Lannigan
Deborah A. Lannigan
The Serine/Threonine protein kinase family, p90 ribosomal S6 kinases (RSK) are downstream effectors of extracellular signal regulated kinase 1/2 (ERK1/2) and are activated in response to tyrosine kinase receptor or G-protein coupled receptor signaling. RSK contains two distinct kinase domains, an N-terminal kinase (NTKD) and a C-terminal kinase (CTKD). The sole function of the CTKD is to aid in the activation of the NTKD, which is responsible for substrate phosphorylation. RSK regulates various homeostatic processes including those involved in transcription, translation and ribosome biogenesis, proliferation and survival, cytoskeleton, nutrient sensing, excitation and inflammation. RSK also acts as a major negative regulator of ERK1/2 signaling. RSK is associated with numerous cancers and has been primarily studied in the context of transformation and metastasis. The development of specific RSK inhibitors as cancer therapeutics has lagged behind that of other members of the mitogen-activated protein kinase signaling pathway. Importantly, a pan-RSK inhibitor, PMD-026, is currently in phase I/1b clinical trials for metastatic breast cancer. However, there are four members of the RSK family, which have overlapping and distinct functions that can vary in a tissue specific manner. Thus, a problem for transitioning a RSK inhibitor to the clinic may be the necessity to develop isoform specific inhibitors, which will be challenging as the NTKDs are very similar to each other. CTKD inhibitors have limited use as therapeutics as they are not able to inhibit the activity of the NTKD but could be used in the development of proteolysis-targeting chimeras.

27 February 2020 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
SKSugyeom Kim
Sugyeom Kim
YLYu Li
Yu Li
LLLin Lin
Lin Lin
PSPeyton R. Sayasith
Peyton R. Sayasith
ATAriel T. Tarr
Ariel T. Tarr
George A O'DohertyGeorge A O'Doherty
George A O'Doherty

1 July 2020 in Cell Reports
Verified
Journal Article
Open access
KLKatarzyna A. Ludwik
Katarzyna A. Ludwik
ZSZachary M. Sandusky
Zachary M. Sandusky
KSKimberly M. Stauffer
Kimberly M. Stauffer
YLYu Li
Yu Li
KBKelli L. Boyd
Kelli L. Boyd
DLDeborah A. Lannigan
Deborah A. Lannigan
In response to estrogens, estrogen receptor alpha (ERα), a critical regulator of homeostasis, is degraded through the 26S proteasome. However, despite the continued presence of estrogen before menopause, ERα protein levels are maintained. We discovered that ERK1/2-RSK2 activity oscillates during the estrous cycle. In response to high estrogen levels, ERK1/2 is activated and phosphorylates ERα to drive ERα degradation and estrogen-responsive gene expression. Reduction of estrogen levels results in ERK1/2 deactivation. RSK2 maintains redox homeostasis, which prevents sustained ERK1/2 activation. In juveniles, ERK1/2-RSK2 activity is not required. Mammary gland regeneration demonstrates that ERK1/2-RSK2 regulation of ERα is intrinsic to the epithelium. Reduced RSK2 and enrichment in an estrogen-regulated gene signature occur in individuals taking oral contraceptives. RSK2 loss enhances DNA damage, which may account for the elevated breast cancer risk with the use of exogenous estrogens. These findings implicate RSK2 as a critical component for the preservation of estrogen homeostasis.

3 February 2020 in Organic Letters
Verified
Journal Article
Closed access
YLYu Li
Yu Li
ZSZachary M. Sandusky
Zachary M. Sandusky
RVRajender Vemula
Rajender Vemula
QZQi Zhang
Qi Zhang
BWBulan Wu
Bulan Wu
George A O'DohertyGeorge A O'Doherty
George A O'Doherty

26 July 2022 in Endocrinology
Verified
Journal Article
Closed access
PDF file
DLDeborah A. Lannigan
Deborah A. Lannigan
Signaling via extracellular regulated kinase 1/2 (ERK1/2) and p90 ribosomal S6 kinase (RSK), a downstream effector, mediates numerous processes. For example, ERK1/2-RSK signaling is essential for estrogen homeostasis in the mammary gland and uterus to maintain physiological responsiveness. This review will focus on the coordination of ERK1/2-RSK2 and estrogen signaling through estrogen receptor alpha (ERα). The interrelationship and the feedback mechanisms between these pathways occurs at the level of transcription, translation, and posttranslational modification. Identifying how ERK1/2-RSK2 and estrogen signaling cooperate in homeostasis and disease may lead to novel therapeutic approaches in estrogen-dependent disorders.

1 January 2021 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
EWEric B. Wright
Eric B. Wright
SFShinji Fukuda
Shinji Fukuda
MLMingzong Li
Mingzong Li
YLYu Li
Yu Li
George A O'DohertyGeorge A O'Doherty
George A O'Doherty
DLDeborah A. Lannigan
Deborah A. Lannigan
Identifying isoform-specific inhibitors for closely related kinase family members remains a substantial challenge. The necessity for achieving this specificity is exemplified by the RSK family, downstream effectors of ERK1/2, which have divergent physiological effects. The natural product, SL0101, a flavonoid glycoside, binds specifically to RSK1/2 through a binding pocket generated by an extensive conformational rearrangement within the RSK N-terminal kinase domain (NTKD). In modelling experiments a single amino acid that is divergent in RSK3/4 most likely prevents the required conformational rearrangement necessary for SL0101 binding. Kinetic analysis of RSK2 association with SL0101 and its derivatives identified that regions outside of the NTKD contribute to stable inhibitor binding. An analogue with an n-propyl-carbamate at the 4” position on the rhamnose moiety was identified that forms a highly stable inhibitor complex with RSK2 but not with RSK1. These results identify a SL0101 modification that will aid the identification of RSK2 specific inhibitors.